Skip to main content

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Terminated · Phase 1, Phase 2 · NCT03374085

Conditions: Multiple Myeloma

At a glance

Research payments reported, 2025
$276,453
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
200

About the trial

Sponsor
Celgene
Tested
CC-92480 (drug), Dexamethasone (drug)
Dates
Started 2018-02-06; completion 2025-10-23
Results posted
Not yet

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.

From ClinicalTrials.gov, last updated 2026-02-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Celgene Corporation reported $276,453 in research payments for this study in 2025 (6 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.